Evidence map›Paper›PMID 41018176›Full record

ArticleFrontiers in neurology2025

Hekun decoction versus Femoston for women with amnestic mild cognitive impairment in early menopause: a randomized, three-arm, double-blind clinical trial.

Ziqi Zhai, Guangyao Lin, Siru Chen, Huicong Liu, Rui Yuan, Xianwei Gao, Xiaorong Ni, Mingjie Shen, Haiying Fan, Wenjun Wang and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Ziqi Zhai *Department of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Guangyao Lin *Department of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Siru Chen *Department of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Huicong LiuDepartment of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Rui YuanSchool of Public Health, Fudan University, Shanghai, China.
Xianwei GaoDepartment of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xiaorong NiShanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Mingjie ShenShuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Haiying FanFengxian Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wenjun WangObstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Yan ZhaoShanghai Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Yan WuShanghai Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Chao GuDepartment of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Chao CongDepartment of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shan XiaoDepartment of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yue ZhangDepartment of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jingchang ZhaoDepartment of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jiayao XuSchool of Public Health, Fudan University, Shanghai, China.
Ye WangObstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Jie ChenFengxian Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yishuang ChenDepartment of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yan ZongDepartment of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Qianjue TangDepartment of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shengnan LiDepartment of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhijie ZhangSchool of Public Health, Fudan University, Shanghai, China.
Lianwei XuDepartment of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Amnestic mild cognitive impairment (aMCI), a prodromal stage of Alzheimer's disease (AD), carries a high risk of progression to dementia. However, few clinical trials have focused on interventions to delay this progression. Hekun Decoction, an herbal-based oral medicine, has shown potential in improving memory loss during early menopause. Here we performed a randomized controlled trial to evaluate the efficacy and safety of Hekun Decoction in women with aMCI. Methods: This prospective, randomized, three-arm, double-blind clinical trial enrolled women aged 40-60 years with aMCI during early menopause. Participants were randomized to Hekun Decoction, Femoston, or placebo for 24 weeks. The primary outcome was the change in the Montreal Cognitive Assessment (MoCA) score at 0 and 24 weeks. The secondary outcomes included the Menopause Rating Scale (MRS), Modified Kupperman Index (KI), and Insomnia Severity Index (ISI), along with adverse events. Results: Between October 2021 and February 2024, a total of 292 patients were randomized to Hekun Decoction ( Conclusion: In women with aMCI during early menopause, Hekun Decoction demonstrated non-inferior efficacy to Femoston in improving cognitive function over 24 weeks, with a favorable safety profile. Notably, women in the Hekun Decoction group showed fewer adverse events compared with Femoston. However, further trials with longer follow-up periods are needed to confirm the efficacy of Hekun Decoction in women with aMCI. Clinical trial registration: http://chictr.org.cn, ChiCTR2000036772.

Indexed as

Alzheimer’s diseaseamnestic mild cognitive impairmentclinical trialearly menopausal womenHekun decoction

Identifiers

PMID41018176
PMCPMC12463637

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.